DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.01
26
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
DaShenLin Pharmaceutical Group Co Ltd
Cost of Revenue
DaShenLin Pharmaceutical Group Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Cost of Revenue
-¥17B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Cost of Revenue
-¥15.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Cost of Revenue
-¥14.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Cost of Revenue
-¥6.6B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Cost of Revenue
-¥12.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Cost of Revenue
-¥2.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
DaShenLin Pharmaceutical Group Co Ltd
Glance View
DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 38,353 full-time employees. The company went IPO on 2017-07-31. The firm's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The firm mainly conducts its business within domestic market.
See Also
What is DaShenLin Pharmaceutical Group Co Ltd's Cost of Revenue?
Cost of Revenue
-17B
CNY
Based on the financial report for Jun 30, 2024, DaShenLin Pharmaceutical Group Co Ltd's Cost of Revenue amounts to -17B CNY.
What is DaShenLin Pharmaceutical Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%
Over the last year, the Cost of Revenue growth was -14%. The average annual Cost of Revenue growth rates for DaShenLin Pharmaceutical Group Co Ltd have been -21% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
